Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome

Kol, Shahar

doi:10.1016/j.fertnstert.2003.05.032

Cited by 166 publications

(108 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The latter has important clinical implications for future use of GnRHagonist triggering, for example, in oocyte donation cycles or in cycles in which GnRH-agonist is administered as an alternative to hCG in patients at risk of ovarian hyperstimulation syndrome (20), followed by freezing all embryos for later frozen-thawed ET.…”

Section: Discussionmentioning

confidence: 99%

Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles

Griesinger

Kolibianakis

Papanikolaou³

et al. 2007

Fertility and Sterility

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles

Griesinger

Kolibianakis

Papanikolaou³

et al. 2007

Fertility and Sterility

View full text Add to dashboard Cite

“…Previously [3], the mechanism of OHSS prevention by GnRH agonist trigger instead of hCG was emphasized, i.e. complete luteolysis.…”

Section: Introductionmentioning

confidence: 99%

GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?

Kol

Solt

2008

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…These advantages paved the way to an "OHSSfree clinic" by applying the freeze-all strategy in OHSS high-risk situations [25,26]. OHSS risk can be estimated by the number of growing follicles [27], but other pertinent clinical aspects should be considered (patient's age, weight, history).…”

Section: Discussionmentioning

confidence: 99%

A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger

Kol

2018

Gynecol Obstet Invest

Self Cite

View full text Add to dashboard Cite

Gonadotropin-releasing hormone (GnRH) antagonist-based ovarian stimulation protocol is gaining popularity. This protocol allows for the use of GnRH agonist as a trigger of final oocyte maturation, instead of the “gold standard” human chorionic gonadotropin (hCG) trigger. GnRH agonist trigger causes quick luteolysis, hence its widespread use in the context of ovarian hyperstimulation syndrome (OHSS) prevention. To secure pregnancy post GnRH agonist trigger, the luteal phase must be supplemented to counteract the luteolysis. Several luteal phase protocols post GnRH agonist trigger have been suggested, most notably based on increasing luteal luteinizing hormone (LH) activity (by adding LH or hCG). The current review aims at delineating a rationale for timing luteal support with a single hCG bolus post GnRH agonist trigger. The review also suggests a set of simple rules that must be followed when designing luteal phase support post GnRH agonist trigger.

show abstract

Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome

Cited by 166 publications

References 31 publications

Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles

Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles

GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?

A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger

Contact Info

Product

Resources

About